Mandate

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 415.9 million

Vinge has advised Hansa Biopharma in connection with a directed share issue through which the company raises proceeds of SEK 415.9 million before transaction costs.

Hansa Biopharma is a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.

Vinge’s team consisted of Dain Hård Nevonen, Amanda Knutsson, Anders Sundin Lundberg and Petter Hellgren.

Related

Vinge advises on the sale of Wais to Sertion

Vinge has advised the sellers in connection with the sale of Wais AB to Sertion AB. Wais conducts operations relating to boiler service and maintenance, flue gas cleaning, mechanical works and fan service for, among others, combined heat and power plants.
May 19, 2025

Vinge advises SBB in connection with its acquisition of shares in PPI against payment through a share issue in-kind

Vinge has advised SBB in connection with the agreement entered into with TRG, a Norwegian group of companies controlled by Kjell Inge Røkke and the principal owner of Aker ASA. Under the agreement, SBB has undertaken to carry out a share issue in-kind to TRG or, as applicable, Aker Property Group.
May 16, 2025

Vinge has advised Stendörren Fastigheter in connection with a directed share issue of approximately SEK 300 million

Vinge has advised the property company Stendörren Fastigheter AB (publ) in connection with a directed share issue through which the company raises proceeds of approximately SEK 300 million before transaction costs.
May 14, 2025